Systematic Reviews
May 5, 2022
Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic et al.
9 citations
BACKGROUND: There is currently renewed interest in the use of psychedelic therapy in the treatment of psychiatric disorders, including depression. The proposed systematic review will aim to identify, evaluate and summarise the psychological processes of change underlying psychedelic therapy for depression in the current literature and consider the implications these processes may have on the...
Transcultural Psychiatry
May 3, 2022
Sunghyun Hong, Maureen D Satyshur, Inger Burnett-Zeigler
Depression stigma is a potential barrier to engagement in and efficacy of depression treatment. This pilot study examined the association of mindfulness with depression stigma among participants in an eight-week mindfulness-based intervention for depressive symptoms. Thirty-one African American women with depressive symptoms were recruited from an urban Federally Qualified Health Center (FQHC)...
CNS Spectrums
May 2, 2022
F. L. Rocha, U. G. Cunha, D. Duarte et al.
Abstract Depression in older adults with multiple medical comorbidities can contribute to clinical deterioration, and increased mortality. Electroconvulsive therapy (ECT) is the first-line treatment for these patients. This study aimed to evaluate the effectiveness and safety of subcutaneous (SC) ketamine as an alternative to ECT. We reviewed the medical records of all consecutive older...
International Journal of Environmental Research and Public Health
May 1, 2022
Ho-Jin Shin, Sung-Hyeon Kim, Hwi-young Cho et al.
Female caregivers of people with disabilities are burdened physically and mentally. To improve these symptoms, an intervention that is easy to apply and has fewer side effects, such as natural healing, has been proposed, but the effect of healing using marine resources is unclear until now. The purpose of this study is to investigate the effect of meditation accompanied with stabilization...
Brain Science
May 1, 2022
Mikell Bursky, Dakota A. Egglefield, Sophie Schiff et al.
Depression is often associated with co-occurring neurocognitive deficits in executive function (EF), processing speed (PS) and emotion regulation (ER), which impact treatment response. Cognitive training targeting these capacities results in improved cognitive function and mood, demonstrating the relationship between cognition and affect, and shedding light on novel targets for...
JMIR Research Protocols
May 1, 2022
Gilmar Gutierrez, Joshua D. Rosenblat, Emily R. Hawken et al.
Background Intravenous (IV) ketamine and intranasal (IN) esketamine have been studied as novel alternatives to manage treatment-resistant depression (TRD). The objective of this observational pilot study is to compare the real-world effectiveness and tolerability of IV ketamine and IN esketamine in the management of unipolar TRD. Objective To compare the effectiveness (primary outcome measure)...
Journal of Psychiatric Research
May 1, 2022
Yazen Alnefeesi, David C J Chen-Li, Ella Krane et al.
177 citations
Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The acute efficacy of ketamine in TRD has been demonstrated in replicated randomised-controlled trials (RCTs), but the generalizability of RCT data to real-world practice is limited. To this end, we conducted a systematic review (Search date: 25/12/2021; 1482 records identified) and meta-analysis of studies...
Clinical Psychological Science
April 29, 2022
Z. Cohen, R. DeRubeis, Rachel Hayes et al.
Depression is highly recurrent, even following successful pharmacological and/or psychological intervention. We aimed to develop clinical prediction models to inform adults with recurrent depression choosing between antidepressant medication (ADM) maintenance or switching to mindfulness-based cognitive therapy (MBCT). Using previously published data (N = 424), we constructed prognostic models...
Expert Opinion on Drug Safety
April 27, 2022
M. Kritzer, C. Pae, P. Masand
ABSTRACT Introduction Racemic ketamine, a derivative of phencyclidine, has been used as a dissociative anesthetic since 1970. In 2000, the first randomized controlled trial showed a rapid relief of depressive symptoms. Since then, intravenous ketamine and intranasal S-ketamine have been validated for the treatment of depression and suicidal ideation following dose-response and double-blind...
Case Reports in Psychiatry
April 26, 2022
Jeremy Weleff, Kelly A. Bryant, Alexsandra Kovacevich et al.
5 citations
Background. Clinical trials have demonstrated that subanesthetic intravenous ketamine exerts antidepressant effects lasting a week or longer postinfusion, as well as antisuicidal effects starting approximately 4 hours postinfusion and lasting 72 hours or longer. These findings have generated considerable enthusiasm within psychiatry. However, reports of treatment-emergent suicide attempts and...